Blackstone Life Sciences and Anthos Therapeutics, Inc. (“Anthos” or the “company”), a transformative, clinical-stage biopharmaceutical company developing innovative therapies for the treatment of cardiometabolic diseases, announced today that the company has entered into an agreement with Novartis to acquire Anthos for up to $3.1 billion. Anthos was founded by Blackstone Life Sciences and Novartis in 2019 with the exclusive global rights from Novartis to develop, manufacture, and commercialize abelacimab, a novel factor XI inhibitor that originated at Novartis, being developed to prevent stroke and systemic embolism in patients with atrial fibrillation as well as to prevent the recurrence of blood clots in patients with cancer.

Blackstone Life Sciences 和 Anthos Therapeutics, Inc.（“Anthos”或“公司”）是一家变革性的临床阶段生物制药公司，致力于开发用于治疗心脏代谢疾病的创新疗法，该公司今天宣布，该公司已与诺华达成协议，以高达 31 亿美元的价格收购 Anthos。Anthos由 Blackstone Life Sciences 和诺华于 2019 年创立，诺华拥有其开发、生产和商业化阿贝拉昔单抗的全球独家权利，阿贝拉昔单抗是一种源自诺华的新型 XI 因子抑制剂，正在开发用于预防心房颤动患者的中风和全身性栓塞以及预防癌症患者的血栓复发。

“Abelacimab has the potential to be an important treatment option for the millions of patients globally with atrial fibrillation at high risk of stroke, and we could not have more conviction in the potential of this asset,” said Bill Meury, Chief Executive Officer at Anthos. “With its deep roots in the cardiovascular space, Novartis is especially well positioned to advance abelacimab’s clinical development and bring this innovative product to healthcare providers and patients. I am deeply grateful to the Anthos and Blackstone Life Sciences teams, the clinical investigators, the patients in our studies, the advocacy community, and many others who have played a role in Anthos’ success over the past six years.”

Anthos 首席执行官 Bill Meury 表示： “阿贝拉昔单抗有可能成为全球数百万患有房颤且中风风险较高的患者的重要治疗选择，我们对这一资产的潜力充满信心。”“诺华在心血管领域根基深厚，因此特别适合推进阿贝拉昔单抗的临床开发，并将这一创新产品带给医疗保健提供者和患者。我非常感谢 Anthos 和 Blackstone Life Sciences 团队、临床研究人员、我们研究中的患者、倡导社区以及过去六年来为 Anthos 的成功做出贡献的许多其他人。”

“We are proud to have launched and helped grow Anthos by acquiring the rights to abelacimab, assembling a world class team, designing the clinical plan and financing its development,” said Dr. Nicholas Galakatos, Chairman of Anthos’ Board of Directors and Global Head of Blackstone Life Sciences. “We believe abelacimab has the potential to be a leader in the new class of Factor XI anticoagulants and are pleased to have Novartis as a committed partner to advance the development and commercialization of abelacimab as a potential treatment option for the millions of patients at risk of strokes. This transaction is an affirmation of Blackstone Life Sciences’ ownership investment strategy, where we seek to find innovative products and build companies around them to meet unmet patient needs.”

Anthos 董事会主席兼 Blackstone Life Sciences 全球负责人 Nicholas Galakatos 博士表示： “我们很荣幸能够通过收购阿贝拉西单抗的权利、组建世界级团队、设计临床计划并资助其开发，帮助 Anthos 成长。我们相信阿贝拉西单抗有潜力成为新型 XI 因子抗凝剂的领导者，并且很高兴能与诺华公司合作，共同推进阿贝拉西单抗的开发和商业化，为数百万面临中风风险的患者提供潜在的治疗选择。此次交易是对 Blackstone Life Sciences 所有权投资战略的肯定，我们寻求寻找创新产品并围绕它们建立公司，以满足尚未满足的患者需求。”

In AZALEA-TIMI 71, abelacimab compared with rivaroxaban (Xarelto) demonstrated a 62% reduction in major bleeding or clinically relevant non-major bleeding, a 67% reduction in major bleeding, and an 89% reduction in gastrointestinal bleeding. The overall clinical benefit of abelacimab prompted the Independent Data Monitoring Committee to discontinue the study early. Results from AZALEA-TIMI 71 were recently published in the New England Journal of Medicine on January 23, 2025.

在 AZALEA-TIMI 71 中，与利伐沙班 (Xarelto) 相比，阿贝拉昔单抗使大出血或临床相关的非大出血减少了 62%，大出血减少了 67%，胃肠道出血减少了 89%。阿贝拉昔单抗的总体临床益处促使独立数据监测委员会提前终止了这项研究。AZALEA-TIMI 71 的结果最近于 2025 年 1 月 23 日发表在《新英格兰医学杂志》上。

Anthos is currently conducting a phase 3 clinical study in patients with atrial fibrillation with high risk for stroke or systemic embolism (LILAC-TIMI 76) as well as two phase 3 studies in patients with cancer-associated thrombosis (ASTER and MAGNOLIA). Data from these trials are expected in the second half of 2026.

Anthos 目前正在对患有中风或全身性栓塞风险较高的房颤患者进行一项 3 期临床研究 (LILAC-TIMI 76)，以及对癌症相关血栓患者进行两项 3 期研究 (ASTER 和 MAGNOLIA)。这些试验的数据预计将在 2026 年下半年公布。

Blackstone Life Sciences’ investment in and commitment to Anthos demonstrate the power of combining its scale and deep operating expertise to build businesses that can help bring innovative products to market and substantially improve patient outcomes.

Blackstone Life Sciences 对 Anthos 的投资和承诺彰显了其结合规模和深厚运营专业知识的力量，可以打造有助于将创新产品推向市场并大幅改善患者治疗效果的企业。